Prostate-specific antigen (PSA)

Immunohistochemical expression

 

polyclonal antibody (Dako A0562)

monoclonal antibody (Dako ER/PR8)

prostatic adenocarcinoma, Gleeson 3

100% (19/19)1

100% (19/19)1

prostatic adenocarcinoma, Gleeson 4/5

95% (strong in 90%)1

70% (strong in 55%)1

seminal vesicle

33% (13/40)1

0/401

lung adenocarcinoma

0/401

0/401

breast adenocarcinoma

0/401

0/401

colonic adenocarcinoma

0/401

0/401

     

 

ER/PR8

breast, adenocarcinomas

0/353

ovary, serous

0/183

ovary, mucinous

1/103

endometrial adenocarcinomas

1/103

pancreas, adenocarcinomas

0/533

ampulla of Vater, adenocarcinomas

0/63

cholangiocarcinoma

0/103

oesophagus, adenocarcinoma

0/213

oesophagus, squamous cell carcinoma

0/73

stomach, adenocarcinomas

1/343

colon, adenocarcinomas

0/473

prostate, adenocarcinomas

18/183

lung, adenocarcinoma

0/463

lung, small cell carcinoma

0/33

lung, squamous cell carcinoma

0/73

mesothelioma

0/63

renal cell carcinoma

0/153

hepatocellular carcinoma

0/63

   

Rarely, pulmonary small cell carcinoma may produce ectopic prostate specific antigen and prostatic acid phosphatase4.

Negative in:

Diagnostic utility

References

1 M Morgan et al. Sensitivity and specificity of PSA Immunohistochemistry: a detailed comparison of monoclonal and polyclonal antibodies. Abstract 184, Pathological Society of Great Britain and Ireland January 2001.

2Bassily, N.H., Vallorosi, C.J., Akdas, G., Montie, J.E. and Rubin, M.A. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol 2000;113:383-8.

3 Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11:3766-72 FULL TEXT

4 Freeman NJ,Doolittle C. Elevated prostate markers in metastatic small cell carcinoma of unknown primary. Cancer 1991; 68:1118-20

©SMUHT/PW Bishop